Samsung Bioepis cancer drug under review by FDA
Korea JoongAng Daily

Home > Business > Industry

print dictionary print

Samsung Bioepis cancer drug under review by FDA

Published: 20 Dec. 2017, 20:00
Samsung Bioepis said Wednesday that the U.S. Food and Drug Administration has begun reviewing its license application for a cancer-fighting biosimilar called SB3.

A biosimilar is a drug with active properties similar to a previously licensed one. SB3 references Herceptin, a breast cancer drug from Swiss pharmaceutical company Roche.

According to Samsung Bioepis, SB3 is the company’s first oncological biosimilar submitted for regulatory review in the United States.


By Kim Jee-hee
tags

More in Industry

ExoRenal aims to give kidney dialysis patients their lives back

LG CNS to go public next year in $5 billion IPO

Travel show 2024 welcomes future tourists

HD Hyundai engine takes top prize at H2 MEET hydrogen show

Emart offers 30 percent discount through Oct. 10

Related Stories

HMM signs $137 million oil shipping contract with S-Oil

80-year-old makes history as oldest contestant in Miss Universe Korea

SHINee's Minho to hold first solo concert in November

[VIDEO] PSG stars train ahead of Arsenal clash

Seosan Haemieupseong Festival to showcase local food, culture at historical fortress
Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
s
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)